452 related articles for article (PubMed ID: 30228268)
1. Immune Checkpoint Inhibitor-Associated Colitis and Hepatitis.
Reddy HG; Schneider BJ; Tai AW
Clin Transl Gastroenterol; 2018 Sep; 9(9):180. PubMed ID: 30228268
[TBL] [Abstract][Full Text] [Related]
2. [Hepatic and digestive adverse events of immune checkpoint inhibitors (anti-CTLA-4 and, anti-PD-1/PD-L1): A clinico-pathological review].
Papouin B; Mussini C; De Martin E; Guettier C
Ann Pathol; 2018 Dec; 38(6):338-351. PubMed ID: 30143243
[TBL] [Abstract][Full Text] [Related]
3. Managing immune checkpoint-blocking antibody side effects.
Postow MA
Am Soc Clin Oncol Educ Book; 2015; ():76-83. PubMed ID: 25993145
[TBL] [Abstract][Full Text] [Related]
4. Management of toxicities of immune checkpoint inhibitors.
Spain L; Diem S; Larkin J
Cancer Treat Rev; 2016 Mar; 44():51-60. PubMed ID: 26874776
[TBL] [Abstract][Full Text] [Related]
5. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
6. Checkpoint Inhibitor-Induced Colitis.
Bellaguarda E; Hanauer S
Am J Gastroenterol; 2020 Feb; 115(2):202-210. PubMed ID: 31922959
[TBL] [Abstract][Full Text] [Related]
7. Acute liver injury in the context of immune checkpoint inhibitor-related colitis treated with infliximab.
Zhang HC; Luo W; Wang Y
J Immunother Cancer; 2019 Feb; 7(1):47. PubMed ID: 30777137
[TBL] [Abstract][Full Text] [Related]
8. Gastrointestinal and Hepatic Complications of Immune Checkpoint Inhibitors.
Cramer P; Bresalier RS
Curr Gastroenterol Rep; 2017 Jan; 19(1):3. PubMed ID: 28124291
[TBL] [Abstract][Full Text] [Related]
9. PD-1 checkpoint inhibition: Toxicities and management.
Hahn AW; Gill DM; Agarwal N; Maughan BL
Urol Oncol; 2017 Dec; 35(12):701-707. PubMed ID: 28889921
[TBL] [Abstract][Full Text] [Related]
10. Dermatologic Reactions to Immune Checkpoint Inhibitors : Skin Toxicities and Immunotherapy.
Sibaud V
Am J Clin Dermatol; 2018 Jun; 19(3):345-361. PubMed ID: 29256113
[TBL] [Abstract][Full Text] [Related]
11. Managing adverse effects of immunotherapy.
Gerson JN; Ramamurthy C; Borghaei H
Clin Adv Hematol Oncol; 2018 May; 16(5):364-374. PubMed ID: 29851932
[TBL] [Abstract][Full Text] [Related]
12. Immune checkpoint inhibitors for nonsmall cell lung cancer treatment.
Chen YM
J Chin Med Assoc; 2017 Jan; 80(1):7-14. PubMed ID: 27693088
[TBL] [Abstract][Full Text] [Related]
13. Hepatotoxicity of immune checkpoint inhibitors: An evolving picture of risk associated with a vital class of immunotherapy agents.
Suzman DL; Pelosof L; Rosenberg A; Avigan MI
Liver Int; 2018 Jun; 38(6):976-987. PubMed ID: 29603856
[TBL] [Abstract][Full Text] [Related]
14. Checkpoint inhibitor colitis: a new model of inflammatory bowel disease?
Siakavellas SI; Bamias G
Curr Opin Gastroenterol; 2018 Nov; 34(6):377-383. PubMed ID: 30157044
[TBL] [Abstract][Full Text] [Related]
15. Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management.
Sznol M; Postow MA; Davies MJ; Pavlick AC; Plimack ER; Shaheen M; Veloski C; Robert C
Cancer Treat Rev; 2017 Jul; 58():70-76. PubMed ID: 28689073
[TBL] [Abstract][Full Text] [Related]
16. Expansion of pharmacist clinical services to optimize the management of immune checkpoint inhibitor toxicities.
Renna CE; Dow EN; Bergsbaken JJ; Leal TA
J Oncol Pharm Pract; 2019 Jun; 25(4):954-960. PubMed ID: 30975067
[TBL] [Abstract][Full Text] [Related]
17. Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.
Herzberg B; Campo MJ; Gainor JF
Oncologist; 2017 Jan; 22(1):81-88. PubMed ID: 27534574
[TBL] [Abstract][Full Text] [Related]
18. Checkpoint inhibitors and gastrointestinal immune-related adverse events.
Pernot S; Ramtohul T; Taieb J
Curr Opin Oncol; 2016 Jul; 28(4):264-8. PubMed ID: 27138569
[TBL] [Abstract][Full Text] [Related]
19. [Advances in immune checkpoint inhibitors in gastrointestinal cancer].
Zhu XR; Zheng LZ
Zhonghua Zhong Liu Za Zhi; 2017 Sep; 39(9):646-649. PubMed ID: 28926891
[TBL] [Abstract][Full Text] [Related]
20. Immune checkpoint inhibitors and the development of granulomatous reactions.
Cornejo CM; Haun P; English J; Rosenbach M
J Am Acad Dermatol; 2019 Nov; 81(5):1165-1175. PubMed ID: 30092327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]